GLG News by Political Experts (outside Washington DC)

1) Accident confirms feelings of increasing skeptical public in Japan and other advanced industrial nations 2) Strong government support for the industry may not be sufficient to alter public perception of nuclear energy 3) Claims that ecologists and green activists will accept n-power are overblow

There are many layers and crosscurrents to the Belarus problem.  Energy is just one of them. First, Lukashenko is the last dictator in his neighborhood (unless you count Putin).  He wants to turn back the clock to the glory days of the Soviet Union.  Some political parties in Russia actually...

The 2008 NASA budget is $17.3 billion.  41 missions are scheduled for the next seven years.  The Science Mission Directorate, which oversees Earth observing satellites, space telescopes and planetary missions, is slated to receive about $5.5 billion of this total, an increase of $49.3 million...

Pirating is part of the general syndrome of corruption Pirated software is not limited to China

According to the “European Attractiveness Survey 2007,” from Ernst and Young, Poland ranked seventh globally among FDI destinations. Due to its productivity, human capital, low labor cost, and flexible employment force, Poland ranked number one in terms of jobs created by FDI with 31,115 new jobs in...

Is there room for an independent candidate in today's politics? Is Michael Bloomberg the independent who could win?

A Senate committee has approved legislation that would create a pathway for biotech drugs to be sold as generics, despite key differences between traditional pharmaceuticals and biotech drugs.  There is one hint as to whether this bill will pass this year:

People watching him as Mayor say he won't run unless it will make a difference. There are only two ways for that to happen.  

Michael Bloomberg's bolt from the Republican Party is no surprise as he gears up for a possible run at the White House in 2008. His candidacy would offer the voters an alternative to either Hillary Rodham Clinton or whomever the Republicans choose as their nominee. Unfortunately for Bloomberg, he will...

Congressional action this week greatly reduces the risk of easy approval for "generic" version of biotech drugs. FDA User Fee legislation approved by a House Committee is similar to the already passed bipartisan Senate bill. The revised version of the House bill that came out of committee no longer...